Thus, our investigation established a new regulatory “miR-182-3p/Myadm/KLF4/p21” axis suggesting the therapeutic significance of miR-182-3p in PAH and the possibility that the myeloid differentiation-directed modification of genes such as Myadm is a potential therapeutic target for PAH. Here, MYADM is linked to pulmonary arterial hypertension.